Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Placebo
DRUG: SRT2104

Sponsor

Sirtris, a GSK Company

Collaborators

[object Object]